While Schering-Plough's boceprevir, to be fair, continues to inch forward, Vertex's competing Teleprevir Next Gen Hep C candidate will post very-impressive "Late Breaking" deveolpments at EASL, in Copenhagen, in a few weeks. Take a look a the EASL PROVE 3 study abstract; then read this snippet from TheStreet.com:
. . . .The new data come from Vertex's PROVE 3 study, which enrolled 453 patients who had failed prior treatment with the current standard drug regimen for hepatitis C -- a 48-week course of long-acting interferon plus ribavirin. In the phase II study, these patients were randomized to receive either treatment with a combination of telaprevir plus the standard therapy or retreatment with the standard therapy alone.
In all, 51% of patients treated with a 24-week regimen that included 12 weeks of telaprevir reported undetectable levels of the hepatitis C virus six months after treatment. In hepatitis C parlance, that's known as a sustained virologic response, or SVR. Simply stated, these patients are considered cured of hepatitis C.
By comparison, only 14% of the patients retreated with 48 weeks of standard therapy alone achieved an SVR, or cure, six months after treatment. . . .
Wow! So, once again, Vertex "goes yard"!